Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$104.46 0.0%	$118.16	$64.11 ▼ $139.13	$5.09B	0.88	681,291 shs	486,786 shs
BPMC Blueprint Medicines	$84.62 +3.1%	$88.61	$73.04 ▼ $121.90	$5.41B	0.75	768,804 shs	634,400 shs
MESO Mesoblast	$10.72 +4.0%	$13.78	$5.06 ▼ $22.00	$1.36B	3.48	277,766 shs	155,755 shs
SRPT Sarepta Therapeutics	$53.79 -0.3%	$82.21	$48.01 ▼ $173.25	$5.22B	0.93	1.41 million shs	1.91 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.01%	+9.21%	-16.27%	+13.63%	+49.85%
BPMC Blueprint Medicines	+3.06%	+5.42%	-5.54%	-23.10%	-4.25%
MESO Mesoblast	+3.98%	+3.08%	-18.54%	-38.03%	+113.97%
SRPT Sarepta Therapeutics	-0.28%	+6.92%	-26.86%	-54.42%	-54.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.5741 of 5 stars	4.5	1.0	4.5	3.3	4.2	0.6
BPMC Blueprint Medicines	2.6715 of 5 stars	4.3	1.0	0.0	3.3	0.8	0.6
MESO Mesoblast	2.5728 of 5 stars	3.5	4.0	0.0	2.6	0.8	0.6
SRPT Sarepta Therapeutics	4.6728 of 5 stars	4.4	2.0	4.2	2.9	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.00	Buy	$169.80	62.55% Upside
BPMC Blueprint Medicines	2.70	Moderate Buy	$124.95	47.65% Upside
MESO Mesoblast	3.00	Buy	$18.00	67.91% Upside
SRPT Sarepta Therapeutics	2.83	Moderate Buy	$161.83	200.85% Upside

Current Analyst Ratings Breakdown

Latest MESO, SRPT, BPMC, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$128.00 ➝ $128.00
4/16/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$75.00 ➝ $75.00
4/11/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$196.00 ➝ $182.00
4/11/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$115.00
4/8/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$133.00 ➝ $133.00
4/7/2025	AXSM Axsome Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$200.00
4/3/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
4/3/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$202.00 ➝ $183.00
4/2/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$75.00 ➝ $75.00
4/1/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$153.00 ➝ $153.00
3/31/2025	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.21	N/A	N/A	$1.18 per share	88.53
BPMC Blueprint Medicines	$508.82M	10.63	N/A	N/A	$4.67 per share	18.12
MESO Mesoblast	$5.67M	240.21	N/A	N/A	$4.21 per share	2.55
SRPT Sarepta Therapeutics	$1.90B	2.74	N/A	N/A	$9.19 per share	5.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.99	N/A	37.04	N/A	-74.47%	-223.51%	-39.88%	5/5/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$1.08	N/A	130.19	N/A	-13.19%	-77.49%	-20.84%	5/1/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	-$535.98M	$2.28	43.03	4.92	N/A	7.43%	11.00%	3.35%	4/29/2025 (Estimated)

Latest MESO, SRPT, BPMC, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	N/A	N/A	N/A	$685.75 million	N/A
5/5/2025	Q1 2025	AXSM Axsome Therapeutics	-$1.23	N/A	N/A	N/A	$121.22 million	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.44	N/A	N/A	N/A	$158.31 million	N/A
2/20/2025	Q4 2024	BPMC Blueprint Medicines	-$0.68	-$0.79	-$0.11	-$0.79	N/A	N/A
2/18/2025	Q4 2024	AXSM Axsome Therapeutics	-$0.97	-$0.96	+$0.01	-$1.54	$117.83 million	$118.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.22	2.11	2.04
BPMC Blueprint Medicines	1.15	2.85	2.80
MESO Mesoblast	0.21	1.18	1.18
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BPMC Blueprint Medicines	N/A
MESO Mesoblast	1.43%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
BPMC Blueprint Medicines	4.21%
MESO Mesoblast	18.80%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	48.77 million	37.84 million	Optionable
BPMC Blueprint Medicines	640	63.91 million	61.22 million	Optionable
MESO Mesoblast	80	127.05 million	103.17 million	Optionable
SRPT Sarepta Therapeutics	840	97.03 million	88.17 million	Optionable

MESO, SRPT, BPMC, and AXSM Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

April 18 at 12:45 PM | accessnewswire.com

Sarepta Therapeutics' (SRPT) Neutral Rating Reiterated at HC Wainwright

April 18 at 8:05 AM | marketbeat.com

Sarepta Therapeutics (SRPT) Receives a Buy from Bank of America Securities

April 17 at 6:09 PM | markets.businessinsider.com

Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week

April 17 at 8:41 AM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

April 16 at 1:30 PM | accessnewswire.com

Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements

April 16 at 9:10 AM | tipranks.com

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

April 16 at 8:35 AM | zacks.com

Cautious Hold Rating on Sarepta Therapeutics Amid Limited LGMD Market and ELEVIDYS Uncertainties

April 16 at 6:40 AM | tipranks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

April 15 at 2:30 PM | accessnewswire.com

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

April 15 at 8:30 AM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

April 14, 2025 | prnewswire.com

F M Investments LLC Acquires Shares of 16,924 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

April 14, 2025 | marketbeat.com

Bank of Nova Scotia Sells 185,102 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

April 14, 2025 | marketbeat.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $163.18 Consensus Price Target from Analysts

April 14, 2025 | americanbankingnews.com

Wells Fargo & Company Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

April 14, 2025 | americanbankingnews.com

Morgan Stanley Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00

April 14, 2025 | americanbankingnews.com

Morgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00

April 13, 2025 | marketbeat.com

Wells Fargo & Company Begins Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

April 13, 2025 | marketbeat.com

Capital Fund Management S.A. Has $21.13 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

April 13, 2025 | marketbeat.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Moderate Buy" by Brokerages

April 13, 2025 | marketbeat.com

SRPT Investigation: Kessler Topaz Meltzer & Check,

April 12, 2025 | kxan.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, SRPT, BPMC, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$104.46 -0.01 (-0.01%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$104.46 0.00 (0.00%)

As of 04/17/2025 05:21 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Blueprint Medicines NASDAQ:BPMC

$84.62 +2.51 (+3.06%)

Closing price 04/17/2025 03:59 PM Eastern

Extended Trading

$81.91 -2.71 (-3.21%)

As of 04/17/2025 04:42 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Mesoblast NASDAQ:MESO

$10.72 +0.41 (+3.98%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$11.52 +0.80 (+7.42%)

As of 04/17/2025 05:15 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Sarepta Therapeutics NASDAQ:SRPT

$53.79 -0.15 (-0.28%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$54.43 +0.64 (+1.18%)

As of 04/17/2025 05:51 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time